27 July 2018
Visiongain’ has launched a new pharma report Global Overactive Bladder Treatment Market 2018-2028: Prescription Drugs, OTC Drugs, Short-term Therapy, Long-term Therapy
It is estimated that about one in six adults in the US and Europe have over active bladder syndrome. The prevalence rate of over active bladder increases with age and thus it is expected that over active bladder will become more common in the future as the average age of people living in the developed countries is significantly increasing. The Global Overactive bladder therapeutic market is growing rapidly, with large opportunity to grow in the untapped APAC region mainly because of the introduction of low-cost generic products in rapidly developing countries such as India and China.
The lead analyst of the report commented “The global overactive bladder therapeutic market is driven by several factors such as increasing prevalence of urinary incontinence, increasing awareness of the disease and its comorbidities, growing diagnosis and treatment rates as well as limited number of current players. Moreover, there are various national and international level policies being adopted by a growing number of countries to combat overactive bladder related symptoms”
Leading companies featured in the report include Allergan, Apotex, Astellas, Medtronic, Mylan, Pfizer, Sanofi.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.
26 February 2021
The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.
22 February 2021
The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.
22 February 2021
The global behavioural Health market has been growing considerably owing to the rising pressure/stress at work, growing incidence and prevalence rate of depression and PTSD (Post Traumatic Stress Disorder) around the globe.